Blood Cell Technologies LLC
Setauket- East Setauket, NY
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 9 Shipyard Ln, Setauket- East Setauket, NY 11733, USA
- Website
- bloodcelltechnologies.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Recombination Therapeutics LLC | Philadelphia, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Senex Biotechnology Inc. | Maynard, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
| Acepre, LLC | Columbia, SC | 325412 Pharmaceutical Preparation Manufacturing |
| Aronora Inc. | Portland, OR | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Blood Cell Technologies LLC is a for-profit limited liability company registered in SAM.gov since August 7, 2014, located in Setauket-East Setauket, New York. The company is classified as a self-certified small disadvantaged business focused on developing novel therapeutic compounds targeting metabolic and redox adaptation pathways in cancer and hematologic diseases. Their core research and development efforts are centered on identifying and optimizing small molecule inhibitors that can potentially address critical medical challenges in oncology and hematology.
Through federal grant awards, Blood Cell Technologies LLC has secured multiple project grants from the National Cancer Institute and National Heart Lung and Blood Institute, primarily targeting research in chemotherapy-induced thrombocytopenia and breast cancer treatment. Their grant-funded work involves developing second-generation BLVRB inhibitors to enhance platelet production and exploring redox-targeted therapeutic strategies for cancer treatment. Specifically, their research has included developing small molecule inhibitors of the BLVRB enzyme, conducting in silico modeling to optimize compound potency, evaluating therapeutic ranges in mouse models, and performing safety studies to determine therapeutic indexes. The company has been awarded grants ranging from $400,000 to support targeted research projects with completion dates extending through August 2026, focusing on innovative approaches to cancer treatment and platelet production enhancement through advanced molecular targeting techniques.
Quick answers
Is Blood Cell Technologies LLC registered in SAM.gov?
Yes. Blood Cell Technologies LLC's SAM.gov registration is active through October 21, 2027.
What is Blood Cell Technologies LLC's CAGE code?
Blood Cell Technologies LLC's CAGE code is 76LR5, and its Unique Entity ID (UEI) is HH9LT9M9B3N4.
What is Blood Cell Technologies LLC's most recent federal award?
Blood Cell Technologies LLC's most recent federal grant award is Development of second generation blvrb inhibitors for treating chemotherapy induced thrombocytopenia (R44CA302180), from National Cancer Institute (NIH), on September 1, 2025.
On GovTribe
See Blood Cell Technologies LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors